pro
“CEO of a clinical stage pharmaceutical company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies.”
Joel Latham, President and CEO of Incannex Healthcare Inc., is responsible for the company’s commercial operations, strategic decision-making, and oversight of all clinical development assets. Joel has 20 years commercial management and executive experience, working for a range multi-national publicly traded companies. Joel can speak to:
Incannex are global leaders in the development of novel medicinal cannabinoid compounds and psychedelic therapies. Incannex is a cannabinoid and psychedelic compound medicine development company undertaking six clinical programs guided by our medical advisory board.
Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
